secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-10-04T23:59:59+00:00
Accession:  0001104659-23-106592
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 1.01, 3.02, 5.02, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome completes merger with Morphimmune, raises $125M PIPE, appoints Clay Siegall as CEO
--------------------------------------------------------------------------------

- Merger closed Oct 2, 2023: Morphimmune stockholders received 0.3042 shares per share; 8.84M shares issued.
- Concurrent PIPE financing of ~$125M at $5.75/share; PIPE investors own 50.7% of post-merger company.
- Prior Immunome stockholders own ~28.6%, prior Morphimmune ~20.7%.
- New board of five directors; Clay Siegall (ex-Seagen CEO) appointed CEO, President, Chairman.
- Material license agreement with Purdue: upfront $200k, milestones up to $3.75M, low single-digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923106592/0001104659-23-106592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923106592/tm2327438d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-106592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer